A new study published in the journal PLOS One has found that terminal cancer patients with refractory pain respond favorably to a marijuana spray containing equal parts THC and CBD.
“This pilot study aimed to assess the safety, tolerability, pharmacokinetics and exploratory analgesic effect of a novel water-soluble oro-buccal nanoparticle spray of a cannabis-based medicine in patients with advanced incurable malignancy with unrelieved pain from opioid analgesic”, states the study, which was conducted by researchers at the University of New South Wales and the University of Sydney.
For this multi-stage study, participants received a marijuana spray containing 2.5 mgs of THC and 2.5 mgs of CBD.
Continue reading